A child with prostaglandin I2-associated thyrotoxicosis

Case report

Yuri Sonoda, Kenichiro Yamamura, Kanako Ishii, Kazuhiro Ohkubo, Kenji Ihara, Yasunari Sakai, Shoichi Ohga

研究成果: ジャーナルへの寄稿記事

抄録

Prostaglandin I2 (PGI2) causes hyperthyroidism, a critical complication in patients with pulmonary arterial hypertension (PAH). However, it remains unknown whether PGI2 may have unfavorable effects on thyroid function in children with congenital portosystemic venous shunt syndrome (CPSVS). We present a boy with CPSVS who developed PAH at seven years of age. During ongoing PGI2 therapy, he experienced thyrotoxicosis at 17 years of age. The literature review showed that the reported 12 patients with PAH (median 11 years of age) developed hyperthyroidism during between one and 11 years of PGI2 treatment. Only one patient survived the acute PAH crisis due to hyperthyroidism. These data provide evidence that prophylactic intervention for hyperthyroidism is indicated for children with CPSVS during PGI2 treatment.

元の言語英語
ページ(範囲)207-210
ページ数4
ジャーナルJCRPE Journal of Clinical Research in Pediatric Endocrinology
11
発行部数2
DOI
出版物ステータス出版済み - 6 1 2019

Fingerprint

Thyrotoxicosis
Epoprostenol
Hyperthyroidism
Pulmonary Hypertension
Thyroid Gland
Therapeutics
Patent Ductus Venosus

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

これを引用

A child with prostaglandin I2-associated thyrotoxicosis : Case report. / Sonoda, Yuri; Yamamura, Kenichiro; Ishii, Kanako; Ohkubo, Kazuhiro; Ihara, Kenji; Sakai, Yasunari; Ohga, Shoichi.

:: JCRPE Journal of Clinical Research in Pediatric Endocrinology, 巻 11, 番号 2, 01.06.2019, p. 207-210.

研究成果: ジャーナルへの寄稿記事

Sonoda, Yuri ; Yamamura, Kenichiro ; Ishii, Kanako ; Ohkubo, Kazuhiro ; Ihara, Kenji ; Sakai, Yasunari ; Ohga, Shoichi. / A child with prostaglandin I2-associated thyrotoxicosis : Case report. :: JCRPE Journal of Clinical Research in Pediatric Endocrinology. 2019 ; 巻 11, 番号 2. pp. 207-210.
@article{5d7eaa7048d84380ba41120b5acfb9c9,
title = "A child with prostaglandin I2-associated thyrotoxicosis: Case report",
abstract = "Prostaglandin I2 (PGI2) causes hyperthyroidism, a critical complication in patients with pulmonary arterial hypertension (PAH). However, it remains unknown whether PGI2 may have unfavorable effects on thyroid function in children with congenital portosystemic venous shunt syndrome (CPSVS). We present a boy with CPSVS who developed PAH at seven years of age. During ongoing PGI2 therapy, he experienced thyrotoxicosis at 17 years of age. The literature review showed that the reported 12 patients with PAH (median 11 years of age) developed hyperthyroidism during between one and 11 years of PGI2 treatment. Only one patient survived the acute PAH crisis due to hyperthyroidism. These data provide evidence that prophylactic intervention for hyperthyroidism is indicated for children with CPSVS during PGI2 treatment.",
author = "Yuri Sonoda and Kenichiro Yamamura and Kanako Ishii and Kazuhiro Ohkubo and Kenji Ihara and Yasunari Sakai and Shoichi Ohga",
year = "2019",
month = "6",
day = "1",
doi = "10.4274/jcrpe.galenos.2018.2018.0169",
language = "English",
volume = "11",
pages = "207--210",
journal = "JCRPE Journal of Clinical Research in Pediatric Endocrinology",
issn = "1308-5727",
publisher = "Galenos Yayincilik",
number = "2",

}

TY - JOUR

T1 - A child with prostaglandin I2-associated thyrotoxicosis

T2 - Case report

AU - Sonoda, Yuri

AU - Yamamura, Kenichiro

AU - Ishii, Kanako

AU - Ohkubo, Kazuhiro

AU - Ihara, Kenji

AU - Sakai, Yasunari

AU - Ohga, Shoichi

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Prostaglandin I2 (PGI2) causes hyperthyroidism, a critical complication in patients with pulmonary arterial hypertension (PAH). However, it remains unknown whether PGI2 may have unfavorable effects on thyroid function in children with congenital portosystemic venous shunt syndrome (CPSVS). We present a boy with CPSVS who developed PAH at seven years of age. During ongoing PGI2 therapy, he experienced thyrotoxicosis at 17 years of age. The literature review showed that the reported 12 patients with PAH (median 11 years of age) developed hyperthyroidism during between one and 11 years of PGI2 treatment. Only one patient survived the acute PAH crisis due to hyperthyroidism. These data provide evidence that prophylactic intervention for hyperthyroidism is indicated for children with CPSVS during PGI2 treatment.

AB - Prostaglandin I2 (PGI2) causes hyperthyroidism, a critical complication in patients with pulmonary arterial hypertension (PAH). However, it remains unknown whether PGI2 may have unfavorable effects on thyroid function in children with congenital portosystemic venous shunt syndrome (CPSVS). We present a boy with CPSVS who developed PAH at seven years of age. During ongoing PGI2 therapy, he experienced thyrotoxicosis at 17 years of age. The literature review showed that the reported 12 patients with PAH (median 11 years of age) developed hyperthyroidism during between one and 11 years of PGI2 treatment. Only one patient survived the acute PAH crisis due to hyperthyroidism. These data provide evidence that prophylactic intervention for hyperthyroidism is indicated for children with CPSVS during PGI2 treatment.

UR - http://www.scopus.com/inward/record.url?scp=85067308060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067308060&partnerID=8YFLogxK

U2 - 10.4274/jcrpe.galenos.2018.2018.0169

DO - 10.4274/jcrpe.galenos.2018.2018.0169

M3 - Article

VL - 11

SP - 207

EP - 210

JO - JCRPE Journal of Clinical Research in Pediatric Endocrinology

JF - JCRPE Journal of Clinical Research in Pediatric Endocrinology

SN - 1308-5727

IS - 2

ER -